Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,461 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押的公告
Regulatory Filings Classification · 62% confidence The document is a corporate announcement by 华邦生命健康股份有限公司 regarding the pledge of shares by its controlling shareholder and related parties. It is not an earnings release, financial report, or dividend notice, nor is it a share repurchase or capital issue by the company itself. It does not fit neatly into any specialized category (e.g., annual report, M&A, or director share transactions). This is a regulatory disclosure of a share pledge event, so it falls into the general regulatory announcements category (RNS).
2026-05-28 Chinese
北京市时代九和律师事务所关于华邦生命健康股份有限公司2025年年度股东会的法律意见书
AGM Information Classification · 90% confidence The document is a formal legal opinion issued by a law firm on the convening, attendance procedures, and resolutions of the company’s 2025 annual shareholders’ meeting (AGM). It verifies the legality of the meeting notices, voting procedures, and voting results. This type of legal opinion is part of the materials provided for the AGM. It is not itself an annual report or a regulatory notice of publication, nor is it a transcript or earnings release. Therefore it best fits AGM Information (materials shared at the Annual General Meeting).
2026-05-15 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions and detailed voting results for each proposal at the company’s 2025 Annual General Meeting (AGM), including share counts and percentages of votes for, against, and abstentions. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” rather than AGM materials or the full annual report. Therefore, it should be classified as DVA.
2026-05-15 Chinese
关于全资子公司获得《药品注册证书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its wholly-owned subsidiary receiving a drug registration certificate from the National Medical Products Administration. It details the drug's specifications, indications, and the impact on the company. The document is short (1293 characters) and is an announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a product approval and does not match other specific categories.
2026-05-07 Chinese
2025年度独立董事述职报告-刘忠海
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025 by an independent director of the company. It details the director's attendance at board and shareholder meetings, committee participation, oversight activities, and compliance with governance and regulatory requirements. The content focuses on the director's duties, governance, and supervisory roles rather than financial results or audit opinions. It is a formal report on the independent director's performance and governance oversight for the year, which aligns with Board/Management Information filings. The document length is 4344 characters, which is substantial and contains detailed narrative rather than a brief announcement or certification. Therefore, it is best classified as Board/Management Information (MANG).
2026-04-22 Chinese
信息披露暂缓、豁免管理制度（2026年4月）
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled 'Information Disclosure Delay and Exemption Management System' for a company, outlining procedures, responsibilities, and regulatory compliance related to information disclosure. It does not contain financial data, earnings, audit results, or any report publication announcement. It is a governance-related document describing internal rules and governance practices regarding disclosure. Therefore, it fits best under Governance Information (CGR). The document length is 2308 characters, which is relatively short but contains substantive governance content, not just an announcement or certification.
2026-04-22 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.